Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical cellular disorders.

Robert J Arceci1, B Jack Longley, Peter D Emanuel

  • 1Div. of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.

Blood neoplasia·2025
Same author

Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions.

Blood neoplasia·2025
Same author

Percutaneous Drainage for Pancreatitis, Panniculitis, and Polyarthritis Syndrome.

Journal of vascular and interventional radiology : JVIR·2025
Same author

Protective effects of dietary grape against atopic dermatitis-like skin lesions in NC/NgaTndCrlj mice.

Frontiers in immunology·2023
Same author

Notch Signaling Suppresses Melanoma Tumor Development in BRAF/Pten Mice.

Cancers·2023
Same author

A Novel In Vitro Culture Model System to Study Merkel Cell Polyomavirus-Associated MCC Using Three-Dimensional Organotypic Raft Equivalents of Human Skin.

Viruses·2021
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This chapter explores atypical cellular disorders, including Langerhans cell histiocytosis (LCH) and mastocytosis, focusing on their underlying mechanisms and novel targeted therapies for better treatment outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Atypical cellular disorders bridge oncology, hematology, and immunology.
  • These rare conditions present clinical challenges and offer insights into disease mechanisms.
  • They serve as models for developing novel targeted therapies.

Purpose of the Study:

  • To provide an overview of atypical cellular disorders.
  • To discuss the pathogenesis, clinical manifestations, and treatment of specific disorders.
  • To explore novel therapeutic approaches based on biological mechanisms.

Main Methods:

  • Review of pathogenesis of Langerhans cell histiocytosis (LCH) as an atypical myeloproliferative syndrome.
  • Analysis of molecular changes in the c-Kit receptor in mastocytosis.

Related Experiment Videos

  • Review of mixed myeloproliferative and myelodysplastic disorders.

    • Main Results:

    • Langerhans cell histiocytosis (LCH) pathogenesis discussed in relation to myeloproliferative syndromes.
    • c-Kit receptor mutations identified as a basis for mastocytosis, guiding targeted therapy development.
    • Review of mixed myeloproliferative and myelodysplastic disorders with novel therapeutic strategies.

    Conclusions:

    • Understanding the biological basis of these disorders is crucial for clinical management.
    • Novel targeted therapies are being developed based on specific molecular and pathogenetic mechanisms.
    • This work offers insights into the biology, clinical aspects, and treatment of atypical cellular disorders.